List view / Grid view
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
A new technology called mass cytometry, or CyTOF, is providing new insights into a range of key proteins in blood cancer cells.
Using AI and deep learning, researchers have enhanced Scanning Probe Microscopy (SPM) and made their automated resource available for scientists.
Drug Target Review explores the findings of a recent review of molecular, cellular, multi-cellular and tissue engineering and modelling technologies for drug design.
New in silico screening software has the capability to screen billions of compounds, with the hope of improving drug design and limiting side effects.
Researchers have used virtual reality (VR) to control how drugs bind to their protein targets, which they say could be useful for designing new treatments.
Researchers have created a new technical resource atlas which maps the 15 distinct cell types involved in muscle repair for disease and therapy research.
Drug Target Review rounds up the latest updates on research into coronavirus treatments, focusing on virtual screening to find therapies for COVID-19.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
A new method for weighing proteins at the atom level, called individual ion mass spectrometry, has been developed by American researchers.
A computational programme has been created by researchers to aid in the design of proteins for therapeutics, to predict interactions.
The newest version of the Unified Data Model (UDM) project has been released, allowing R&D scientists to access information on compound synthesis and testing.
25 February 2020 | By Bruker Daltonics
Learn about the latest software tools for Bruker Daltonic’s SPR instrumentation and explore high-throughput screening strategies enabled by their ecosystem.
A new antibiotic compound has been identified by researchers who designed a machine-learning algorithm to screen millions of molecules.
A collaboration of academic institutions in the United States has identified a gene that is linked to alternative splicing changes that occur in several cancers.
